A Phase II Trial of Prolonged Oral Etoposide (VP-16) as Second-Line Therapy for Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

Prolonged oral etoposide is an active regimen in small and nonsmall cell carcinoma of the lung, carcinomas of the breast and ovary, germ cell tumors, and in lymphoma. A Phase II trial was conducted by the Gynecologic Oncology Group to determine its activity in endometrial carcinoma. Twenty-six patie...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 1996-10, Vol.63 (1), p.101-104
Main Authors: Rose, Peter G., Blessing, John A., Lewandowski, George S., Creasman, William T., Webster, Kenneth D.
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Administration, Oral
Biological and medical sciences
Cohort Studies
Endometrial Neoplasms - drug therapy
Endometrial Neoplasms - pathology
Etoposide - administration & dosage
Etoposide - adverse effects
Etoposide - therapeutic use
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Leukopenia - chemically induced
Medical sciences
Neoplasm Recurrence, Local
Thrombocytopenia - chemically induced
Time Factors
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prolonged oral etoposide is an active regimen in small and nonsmall cell carcinoma of the lung, carcinomas of the breast and ovary, germ cell tumors, and in lymphoma. A Phase II trial was conducted by the Gynecologic Oncology Group to determine its activity in endometrial carcinoma. Twenty-six patients with advanced or recurrent endometrial carcinoma were entered into study; one patient was ineligible because of an incorrect cell type. The remaining eligible patients were treated with etoposide at a starting dose of 50 mg/m2/day (30 mg/m2/day with prior radiotherapy) for 21 days. Based on hematologic toxicity, a dose escalation to a maximum dose of 60 mg/m2/day was prescribed. Twenty-two patients were evaluable for response and 25 were evaluable for toxicity. Fourteen had received prior radiotherapy and 24 had received prior chemotherapy. A median of two courses were given (range, 1–10). Grade 3 or 4 leukopenia occurring in 52% was the most common complication (grade 3, 36%; grade 4, 16%). Grade 4 thrombocytopenia occurred in 16% of patients. There were no objective responses including four patients with serous papillary carcinoma. This regimen is not significantly active as second-line therapy in endometrial carcinoma.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.1996.0286